$CMI
CUMMINS INC Stock $cmi

$cmi Overview Financials Valuation SEC Filings Company Website

2024 Q1 Form 10-Q Financial Statement

#000002617224000023 Filed on May 02, 2024

Income Statement

Concept	2024 Q1
Revenue	$8.403B
YoY Change	-0.59%
Cost Of Revenue	$6.362B
YoY Change	-0.97%
Gross Profit	$2.041B
YoY Change	0.59%
Gross Profit Margin	24.29%
Selling, General & Admin	$839.0M
YoY Change	11.42%
% of Gross Profit	41.11%
Research & Development	$369.0M
YoY Change	5.43%
% of Gross Profit	18.08%
Depreciation & Amortization	$265.0M
YoY Change	7.72%
% of Gross Profit	12.98%
Operating Expenses	$1.208B
YoY Change	9.52%
Operating Profit	$923.0M
YoY Change	-10.04%
Interest Expense	$89.00M
YoY Change	2.3%
% of Operating Profit	9.64%
Other Income/Expense, Net	$1.387B
YoY Change	1441.11%
Pretax Income	$2.221B
YoY Change	115.84%
Income Tax	$193.0M
% Of Pretax Income	8.69%
Net Earnings	$2.028B
YoY Change	151.61%
Net Earnings / Revenue	24.13%
Basic Earnings Per Share	$14.10
Diluted Earnings Per Share	$14.03
COMMON SHARES
Basic Shares Outstanding	141.9M shares
Diluted Shares Outstanding	142.1M shares

Balance Sheet

Concept	2024 Q1
SHORT-TERM ASSETS
Cash & Short-Term Investments	$3.051B
YoY Change	25.09%
Cash & Equivalents	$2.541B
Short-Term Investments	$510.0M
Other Short-Term Assets	$1.348B
YoY Change	10.76%
Inventory	$5.758B
Prepaid Expenses
Receivables	$5.463B
Other Receivables	$0.00
Total Short-Term Assets	$15.62B
YoY Change	1.64%
LONG-TERM ASSETS
Property, Plant & Equipment	$6.011B
YoY Change	7.53%
Goodwill	$2.406B
YoY Change	1.73%
Intangibles	$2.455B
YoY Change	-7.01%
Long-Term Investments	$1.774B
YoY Change	-4.62%
Other Assets	$2.374B
YoY Change	12.3%
Total Long-Term Assets	$16.21B
YoY Change	0.88%
TOTAL ASSETS
Total Short-Term Assets	$15.62B
Total Long-Term Assets	$16.21B
Total Assets	$31.83B
YoY Change	1.25%
SHORT-TERM LIABILITIES
YoY Change
Accounts Payable	$4.476B
YoY Change	-3.45%
Accrued Expenses	$3.697B
YoY Change	124.33%
Deferred Revenue	$1.236B
YoY Change	18.85%
Short-Term Debt	$951.0M
YoY Change	-65.72%
Long-Term Debt Due	$113.0M
YoY Change	-80.14%
Total Short-Term Liabilities	$11.69B
YoY Change	-1.99%
LONG-TERM LIABILITIES
Long-Term Debt	$5.771B
YoY Change	30.89%
Other Long-Term Liabilities	$3.208B
YoY Change	-2.28%
Total Long-Term Liabilities	$3.208B
YoY Change	-2.28%
TOTAL LIABILITIES
Total Short-Term Liabilities	$11.69B
Total Long-Term Liabilities	$3.208B
Total Liabilities	$21.73B
YoY Change	5.71%
SHAREHOLDERS EQUITY
Retained Earnings	$19.61B
YoY Change	5.37%
Common Stock
YoY Change
Preferred Stock
YoY Change
Treasury Stock (at cost)	$10.83B
YoY Change	15.36%
Treasury Stock Shares
Shareholders Equity	$9.067B
YoY Change
Total Liabilities & Shareholders Equity	$31.83B
YoY Change	1.25%

Cashflow Statement

Concept	2024 Q1
OPERATING ACTIVITIES
Net Income	$2.028B
YoY Change	151.61%
Depreciation, Depletion And Amortization	$265.0M
YoY Change	7.72%
Cash From Operating Activities	$276.0M
YoY Change	-44.24%
INVESTING ACTIVITIES
Capital Expenditures	$169.0M
YoY Change	-12.44%
Acquisitions	$59.00M
YoY Change
Other Investing Activities	$56.00M
YoY Change	3.7%
Cash From Investing Activities	-$406.0M
YoY Change	78.07%
FINANCING ACTIVITIES
Cash Dividend Paid	$239.0M
YoY Change	7.66%
Common Stock Issuance & Retirement, Net
YoY Change
Debt Paid & Issued, Net
YoY Change
Cash From Financing Activities	$499.0M
YoY Change	-237.47%
NET CHANGE
Cash From Operating Activities	$276.0M
Cash From Investing Activities	-$406.0M
Cash From Financing Activities	$499.0M
Net Change In Cash	$362.0M
YoY Change	-399.17%
FREE CASH FLOW
Cash From Operating Activities	$276.0M
Capital Expenditures	$169.0M
Free Cash Flow	$107.0M
YoY Change	-64.57%

Facts In Submission

Frame	Concept Type	Concept / XBRL Key	Value	Unit
CY2024Q1	us-gaap	Cost Of Revenue CostOfRevenue	6362000000	usd
CY2023Q1	us-gaap	Cost Of Revenue CostOfRevenue	6424000000	usd
CY2024Q1	us-gaap	Gross Profit GrossProfit	2041000000	usd
CY2023Q1	us-gaap	Gross Profit GrossProfit	2029000000	usd
CY2024Q1	us-gaap	Selling General And Administrative Expense SellingGeneralAndAdministrativeExpense	839000000	usd
CY2023Q1	us-gaap	Selling General And Administrative Expense SellingGeneralAndAdministrativeExpense	753000000	usd
CY2024Q1	us-gaap	Research And Development Expense ResearchAndDevelopmentExpense	369000000	usd
CY2023Q1	us-gaap	Research And Development Expense ResearchAndDevelopmentExpense	350000000	usd
CY2024Q1	us-gaap	Income Loss From Equity Method Investments IncomeLossFromEquityMethodInvestments	123000000	usd
CY2023Q1	us-gaap	Income Loss From Equity Method Investments IncomeLossFromEquityMethodInvestments	119000000	usd
CY2024Q1	us-gaap	Other Operating Income Expense Net OtherOperatingIncomeExpenseNet	-33000000	usd
CY2023Q1	us-gaap	Other Operating Income Expense Net OtherOperatingIncomeExpenseNet	-19000000	usd
CY2024Q1	us-gaap	Operating Income Loss OperatingIncomeLoss	923000000	usd
CY2023Q1	us-gaap	Operating Income Loss OperatingIncomeLoss	1026000000	usd
CY2024Q1	us-gaap	Interest Expense InterestExpense	89000000	usd
CY2023Q1	us-gaap	Interest Expense InterestExpense	87000000	usd
CY2024Q1	us-gaap	Other Nonoperating Income Expense OtherNonoperatingIncomeExpense	1387000000	usd
CY2023Q1	us-gaap	Other Nonoperating Income Expense OtherNonoperatingIncomeExpense	90000000	usd
CY2024Q1	us-gaap	Income Loss Including Portion Attributable To Noncontrolling Interest IncomeLossIncludingPortionAttributableToNoncontrollingInterest	2221000000	usd
CY2024Q1	us-gaap	Property Plant And Equipment Net PropertyPlantAndEquipmentNet	6011000000	usd
CY2023Q1	us-gaap	Income Loss Including Portion Attributable To Noncontrolling Interest IncomeLossIncludingPortionAttributableToNoncontrollingInterest	1029000000	usd
CY2024Q1	us-gaap	Income Tax Expense Benefit IncomeTaxExpenseBenefit	193000000	usd
CY2023Q1	us-gaap	Income Tax Expense Benefit IncomeTaxExpenseBenefit	223000000	usd
CY2024Q1	us-gaap	Profit Loss ProfitLoss	2028000000	usd
CY2023Q1	us-gaap	Profit Loss ProfitLoss	806000000	usd
CY2024Q1	us-gaap	Net Income Loss Attributable To Noncontrolling Interest NetIncomeLossAttributableToNoncontrollingInterest	35000000	usd
CY2023Q1	us-gaap	Net Income Loss Attributable To Noncontrolling Interest NetIncomeLossAttributableToNoncontrollingInterest	16000000	usd
CY2024Q1	us-gaap	Net Income Loss Available To Common Stockholders Basic NetIncomeLossAvailableToCommonStockholdersBasic	1993000000	usd
CY2023Q1	us-gaap	Net Income Loss Available To Common Stockholders Basic NetIncomeLossAvailableToCommonStockholdersBasic	790000000	usd
CY2024Q1	us-gaap	Earnings Per Share Basic EarningsPerShareBasic	14.10
CY2023Q1	us-gaap	Earnings Per Share Basic EarningsPerShareBasic	5.58
CY2024Q1	us-gaap	Earnings Per Share Diluted EarningsPerShareDiluted	14.03
CY2023Q1	us-gaap	Earnings Per Share Diluted EarningsPerShareDiluted	5.55
CY2024Q1	us-gaap	Weighted Average Number Of Shares Outstanding Basic WeightedAverageNumberOfSharesOutstandingBasic	141300000	shares
CY2023Q1	us-gaap	Weighted Average Number Of Shares Outstanding Basic WeightedAverageNumberOfSharesOutstandingBasic	141500000	shares
CY2024Q1	us-gaap	Incremental Common Shares Attributable To Share Based Payment Arrangements IncrementalCommonSharesAttributableToShareBasedPaymentArrangements	800000	shares
CY2023Q1	us-gaap	Incremental Common Shares Attributable To Share Based Payment Arrangements IncrementalCommonSharesAttributableToShareBasedPaymentArrangements	900000	shares
CY2024Q1	us-gaap	Weighted Average Number Of Diluted Shares Outstanding WeightedAverageNumberOfDilutedSharesOutstanding	142100000	shares
CY2023Q1	us-gaap	Weighted Average Number Of Diluted Shares Outstanding WeightedAverageNumberOfDilutedSharesOutstanding	142400000	shares
CY2024Q1	us-gaap	Profit Loss ProfitLoss	2028000000	usd
CY2023Q1	us-gaap	Profit Loss ProfitLoss	806000000	usd
CY2024Q1	us-gaap	Other Comprehensive Income Loss Pension And Other Postretirement Benefit Plans Adjustment Net Of Tax OtherComprehensiveIncomeLossPensionAndOtherPostretirementBenefitPlansAdjustmentNetOfTax	13000000	usd
CY2023Q1	us-gaap	Other Comprehensive Income Loss Pension And Other Postretirement Benefit Plans Adjustment Net Of Tax OtherComprehensiveIncomeLossPensionAndOtherPostretirementBenefitPlansAdjustmentNetOfTax	9000000	usd
CY2024Q1	us-gaap	Other Comprehensive Income Loss Foreign Currency Transaction And Translation Adjustment Net Of Tax OtherComprehensiveIncomeLossForeignCurrencyTransactionAndTranslationAdjustmentNetOfTax	-60000000	usd
CY2023Q1	us-gaap	Other Comprehensive Income Loss Foreign Currency Transaction And Translation Adjustment Net Of Tax OtherComprehensiveIncomeLossForeignCurrencyTransactionAndTranslationAdjustmentNetOfTax	82000000	usd
CY2024Q1	us-gaap	Other Comprehensive Income Loss Cash Flow Hedge Gain Loss After Reclassification And Tax OtherComprehensiveIncomeLossCashFlowHedgeGainLossAfterReclassificationAndTax	12000000	usd
CY2023Q1	us-gaap	Other Comprehensive Income Loss Cash Flow Hedge Gain Loss After Reclassification And Tax OtherComprehensiveIncomeLossCashFlowHedgeGainLossAfterReclassificationAndTax	-3000000	usd
CY2024Q1	us-gaap	Other Comprehensive Income Loss Net Of Tax OtherComprehensiveIncomeLossNetOfTax	-61000000	usd
CY2023Q1	us-gaap	Other Comprehensive Income Loss Net Of Tax OtherComprehensiveIncomeLossNetOfTax	70000000	usd
CY2024Q1	us-gaap	Comprehensive Income Net Of Tax Including Portion Attributable To Noncontrolling Interest ComprehensiveIncomeNetOfTaxIncludingPortionAttributableToNoncontrollingInterest	1967000000	usd
CY2023Q1	us-gaap	Comprehensive Income Net Of Tax Including Portion Attributable To Noncontrolling Interest ComprehensiveIncomeNetOfTaxIncludingPortionAttributableToNoncontrollingInterest	876000000	usd
CY2024Q1	us-gaap	Comprehensive Income Net Of Tax Attributable To Noncontrolling Interest ComprehensiveIncomeNetOfTaxAttributableToNoncontrollingInterest	32000000	usd
CY2023Q1	us-gaap	Comprehensive Income Net Of Tax Attributable To Noncontrolling Interest ComprehensiveIncomeNetOfTaxAttributableToNoncontrollingInterest	19000000	usd
CY2024Q1	us-gaap	Comprehensive Income Net Of Tax ComprehensiveIncomeNetOfTax	1935000000	usd
CY2023Q1	us-gaap	Comprehensive Income Net Of Tax ComprehensiveIncomeNetOfTax	857000000	usd
CY2024Q1	us-gaap	Cash And Cash Equivalents At Carrying Value CashAndCashEquivalentsAtCarryingValue	2541000000	usd
CY2023Q4	us-gaap	Cash And Cash Equivalents At Carrying Value CashAndCashEquivalentsAtCarryingValue	2179000000	usd
CY2024Q1	us-gaap	Marketable Securities Current MarketableSecuritiesCurrent	510000000	usd
CY2023Q4	us-gaap	Marketable Securities Current MarketableSecuritiesCurrent	562000000	usd
CY2024Q1	us-gaap	Cash Cash Equivalents And Short Term Investments CashCashEquivalentsAndShortTermInvestments	3051000000	usd
CY2023Q4	us-gaap	Cash Cash Equivalents And Short Term Investments CashCashEquivalentsAndShortTermInvestments	2741000000	usd
CY2024Q1	us-gaap	Accounts Receivable Net AccountsReceivableNet	5463000000	usd
CY2023Q4	us-gaap	Accounts Receivable Net AccountsReceivableNet	5583000000	usd
CY2024Q1	us-gaap	Inventory Net InventoryNet	5758000000	usd
CY2023Q4	us-gaap	Inventory Net InventoryNet	5677000000	usd
CY2024Q1	us-gaap	Prepaid Expense And Other Assets Current PrepaidExpenseAndOtherAssetsCurrent	1348000000	usd
CY2023Q4	us-gaap	Prepaid Expense And Other Assets Current PrepaidExpenseAndOtherAssetsCurrent	1197000000	usd
CY2024Q1	us-gaap	Assets Current AssetsCurrent	15620000000	usd
CY2023Q4	us-gaap	Assets Current AssetsCurrent	15198000000	usd
CY2024Q1	us-gaap	Property Plant And Equipment Gross PropertyPlantAndEquipmentGross	11253000000	usd
CY2023Q4	us-gaap	Property Plant And Equipment Gross PropertyPlantAndEquipmentGross	11674000000	usd
CY2024Q1	us-gaap	Accumulated Depreciation Depletion And Amortization Property Plant And Equipment AccumulatedDepreciationDepletionAndAmortizationPropertyPlantAndEquipment	5242000000	usd
CY2023Q4	us-gaap	Accumulated Depreciation Depletion And Amortization Property Plant And Equipment AccumulatedDepreciationDepletionAndAmortizationPropertyPlantAndEquipment	5425000000	usd
CY2023Q4	us-gaap	Property Plant And Equipment Net PropertyPlantAndEquipmentNet	6249000000	usd
CY2024Q1	us-gaap	Investments In Affiliates Subsidiaries Associates And Joint Ventures InvestmentsInAffiliatesSubsidiariesAssociatesAndJointVentures	1774000000	usd
CY2023Q4	us-gaap	Investments In Affiliates Subsidiaries Associates And Joint Ventures InvestmentsInAffiliatesSubsidiariesAssociatesAndJointVentures	1800000000	usd
CY2024Q1	us-gaap	Goodwill Goodwill	2406000000	usd
CY2023Q4	us-gaap	Goodwill Goodwill	2499000000	usd
CY2024Q1	us-gaap	Intangible Assets Net Excluding Goodwill IntangibleAssetsNetExcludingGoodwill	2455000000	usd
CY2023Q4	us-gaap	Intangible Assets Net Excluding Goodwill IntangibleAssetsNetExcludingGoodwill	2519000000	usd
CY2024Q1	us-gaap	Defined Benefit Plan Assets For Plan Benefits Noncurrent DefinedBenefitPlanAssetsForPlanBenefitsNoncurrent	1187000000	usd
CY2023Q4	us-gaap	Defined Benefit Plan Assets For Plan Benefits Noncurrent DefinedBenefitPlanAssetsForPlanBenefitsNoncurrent	1197000000	usd
CY2024Q1	us-gaap	Other Assets Noncurrent OtherAssetsNoncurrent	2374000000	usd
CY2023Q4	us-gaap	Other Assets Noncurrent OtherAssetsNoncurrent	2543000000	usd
CY2024Q1	us-gaap	Assets Assets	31827000000	usd
CY2023Q4	us-gaap	Assets Assets	32005000000	usd
CY2024Q1	us-gaap	Accounts Payable Current AccountsPayableCurrent	4476000000	usd
CY2023Q4	us-gaap	Accounts Payable Current AccountsPayableCurrent	4260000000	usd
CY2024Q1	us-gaap	Short Term Bank Loans And Notes Payable ShortTermBankLoansAndNotesPayable	342000000	usd
CY2023Q4	us-gaap	Short Term Bank Loans And Notes Payable ShortTermBankLoansAndNotesPayable	280000000	usd
CY2024Q1	us-gaap	Commercial Paper CommercialPaper	609000000	usd
CY2023Q4	us-gaap	Commercial Paper CommercialPaper	1496000000	usd
CY2024Q1	us-gaap	Long Term Debt Current LongTermDebtCurrent	113000000	usd
CY2023Q4	us-gaap	Long Term Debt Current LongTermDebtCurrent	118000000	usd
CY2024Q1	us-gaap	Employee Related Liabilities Current EmployeeRelatedLiabilitiesCurrent	561000000	usd
CY2023Q4	us-gaap	Employee Related Liabilities Current EmployeeRelatedLiabilitiesCurrent	1108000000	usd
CY2024Q1	us-gaap	Product Warranty Accrual Classified Current ProductWarrantyAccrualClassifiedCurrent	652000000	usd
CY2023Q4	us-gaap	Product Warranty Accrual Classified Current ProductWarrantyAccrualClassifiedCurrent	667000000	usd
CY2024Q1	us-gaap	Contract With Customer Liability Current ContractWithCustomerLiabilityCurrent	1236000000	usd
CY2023Q4	us-gaap	Contract With Customer Liability Current ContractWithCustomerLiabilityCurrent	1220000000	usd
CY2024Q1	us-gaap	Accrued Liabilities Current AccruedLiabilitiesCurrent	3697000000	usd
CY2023Q4	us-gaap	Accrued Liabilities Current AccruedLiabilitiesCurrent	3754000000	usd
CY2024Q1	us-gaap	Liabilities Current LiabilitiesCurrent	11686000000	usd
CY2023Q4	us-gaap	Liabilities Current LiabilitiesCurrent	12903000000	usd
CY2024Q1	us-gaap	Long Term Debt And Capital Lease Obligations LongTermDebtAndCapitalLeaseObligations	5771000000	usd
CY2023Q4	us-gaap	Long Term Debt And Capital Lease Obligations LongTermDebtAndCapitalLeaseObligations	4802000000	usd
CY2024Q1	us-gaap	Contract With Customer Liability Noncurrent ContractWithCustomerLiabilityNoncurrent	1061000000	usd
CY2023Q4	us-gaap	Contract With Customer Liability Noncurrent ContractWithCustomerLiabilityNoncurrent	966000000	usd
CY2024Q1	us-gaap	Other Liabilities Noncurrent OtherLiabilitiesNoncurrent	3208000000	usd
CY2023Q4	us-gaap	Other Liabilities Noncurrent OtherLiabilitiesNoncurrent	3430000000	usd
CY2024Q1	us-gaap	Liabilities Liabilities	21726000000	usd
CY2023Q4	us-gaap	Liabilities Liabilities	22101000000	usd
CY2024Q1	us-gaap	Commitments And Contingencies CommitmentsAndContingencies		usd
CY2023Q4	us-gaap	Commitments And Contingencies CommitmentsAndContingencies		usd
CY2024Q1	us-gaap	Common Stock Par Or Stated Value Per Share CommonStockParOrStatedValuePerShare	2.50
CY2024Q1	us-gaap	Common Stock Shares Authorized CommonStockSharesAuthorized	500000000	shares
CY2024Q1	us-gaap	Common Stock Shares Issued CommonStockSharesIssued	222500000	shares
CY2023Q4	us-gaap	Common Stock Shares Issued CommonStockSharesIssued	222500000	shares
CY2024Q1	us-gaap	Common Stock Value Outstanding CommonStockValueOutstanding	2557000000	usd
CY2023Q4	us-gaap	Common Stock Value Outstanding CommonStockValueOutstanding	2564000000	usd
CY2024Q1	us-gaap	Retained Earnings Accumulated Deficit RetainedEarningsAccumulatedDeficit	19605000000	usd
CY2023Q4	us-gaap	Retained Earnings Accumulated Deficit RetainedEarningsAccumulatedDeficit	17851000000	usd
CY2024Q1	us-gaap	Treasury Stock Common Shares TreasuryStockCommonShares	85700000	shares
CY2023Q4	us-gaap	Treasury Stock Common Shares TreasuryStockCommonShares	80700000	shares
CY2024Q1	us-gaap	Treasury Stock Value TreasuryStockValue	10831000000	usd
CY2023Q4	us-gaap	Treasury Stock Value TreasuryStockValue	9359000000	usd
CY2024Q1	us-gaap	Accumulated Other Comprehensive Income Loss Net Of Tax AccumulatedOtherComprehensiveIncomeLossNetOfTax	-2264000000	usd
CY2023Q4	us-gaap	Accumulated Other Comprehensive Income Loss Net Of Tax AccumulatedOtherComprehensiveIncomeLossNetOfTax	-2206000000	usd
CY2024Q1	us-gaap	Stockholders Equity StockholdersEquity	9067000000	usd
CY2023Q4	us-gaap	Stockholders Equity StockholdersEquity	8850000000	usd
CY2024Q1	us-gaap	Minority Interest MinorityInterest	1034000000	usd
CY2023Q4	us-gaap	Minority Interest MinorityInterest	1054000000	usd
CY2024Q1	us-gaap	Stockholders Equity Including Portion Attributable To Noncontrolling Interest StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest	10101000000	usd
CY2023Q4	us-gaap	Stockholders Equity Including Portion Attributable To Noncontrolling Interest StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest	9904000000	usd
CY2024Q1	us-gaap	Liabilities And Stockholders Equity LiabilitiesAndStockholdersEquity	31827000000	usd
CY2023Q4	us-gaap	Liabilities And Stockholders Equity LiabilitiesAndStockholdersEquity	32005000000	usd
CY2024Q1	us-gaap	Profit Loss ProfitLoss	2028000000	usd
CY2023Q1	us-gaap	Profit Loss ProfitLoss	806000000	usd
CY2024Q1	us-gaap	Gain Loss On Sale Of Business GainLossOnSaleOfBusiness	-1333000000	usd
CY2023Q1	us-gaap	Gain Loss On Sale Of Business GainLossOnSaleOfBusiness	0	usd
CY2024Q1	us-gaap	Depreciation Depletion And Amortization DepreciationDepletionAndAmortization	265000000	usd
CY2023Q1	us-gaap	Depreciation Depletion And Amortization DepreciationDepletionAndAmortization	246000000	usd
CY2024Q1	us-gaap	Deferred Income Taxes And Tax Credits DeferredIncomeTaxesAndTaxCredits	-38000000	usd
CY2023Q1	us-gaap	Deferred Income Taxes And Tax Credits DeferredIncomeTaxesAndTaxCredits	-38000000	usd
CY2024Q1	us-gaap	Income Loss From Equity Method Investments Net Of Dividends Or Distributions IncomeLossFromEquityMethodInvestmentsNetOfDividendsOrDistributions	78000000	usd
CY2023Q1	us-gaap	Income Loss From Equity Method Investments Net Of Dividends Or Distributions IncomeLossFromEquityMethodInvestmentsNetOfDividendsOrDistributions	67000000	usd
CY2024Q1	us-gaap	Pension And Other Postretirement Benefits Expense Reversal Of Expense Noncash PensionAndOtherPostretirementBenefitsExpenseReversalOfExpenseNoncash	9000000	usd
CY2023Q1	us-gaap	Pension And Other Postretirement Benefits Expense Reversal Of Expense Noncash PensionAndOtherPostretirementBenefitsExpenseReversalOfExpenseNoncash	1000000	usd
CY2024Q1	us-gaap	Pension And Other Postretirement Benefit Contributions PensionAndOtherPostretirementBenefitContributions	48000000	usd
CY2023Q1	us-gaap	Pension And Other Postretirement Benefit Contributions PensionAndOtherPostretirementBenefitContributions	92000000	usd
CY2024Q1	us-gaap	Increase Decrease In Accounts And Notes Receivable IncreaseDecreaseInAccountsAndNotesReceivable	11000000	usd
CY2023Q1	us-gaap	Increase Decrease In Accounts And Notes Receivable IncreaseDecreaseInAccountsAndNotesReceivable	621000000	usd
CY2024Q1	us-gaap	Increase Decrease In Inventories IncreaseDecreaseInInventories	354000000	usd
CY2023Q1	us-gaap	Increase Decrease In Inventories IncreaseDecreaseInInventories	263000000	usd
CY2024Q1	us-gaap	Increase Decrease In Other Operating Assets IncreaseDecreaseInOtherOperatingAssets	175000000	usd
CY2023Q1	us-gaap	Increase Decrease In Other Operating Assets IncreaseDecreaseInOtherOperatingAssets	142000000	usd
CY2024Q1	us-gaap	Increase Decrease In Accounts Payable IncreaseDecreaseInAccountsPayable	327000000	usd
CY2023Q1	us-gaap	Increase Decrease In Accounts Payable IncreaseDecreaseInAccountsPayable	381000000	usd
CY2024Q1	us-gaap	Increase Decrease In Accrued Liabilities IncreaseDecreaseInAccruedLiabilities	-393000000	usd
CY2023Q1	us-gaap	Increase Decrease In Accrued Liabilities IncreaseDecreaseInAccruedLiabilities	151000000	usd
CY2024Q1	us-gaap	Other Noncash Income Expense OtherNoncashIncomeExpense	-77000000	usd
CY2023Q1	us-gaap	Other Noncash Income Expense OtherNoncashIncomeExpense	-133000000	usd
CY2024Q1	us-gaap	Net Cash Provided By Used In Operating Activities NetCashProvidedByUsedInOperatingActivities	276000000	usd
CY2023Q1	us-gaap	Net Cash Provided By Used In Operating Activities NetCashProvidedByUsedInOperatingActivities	495000000	usd
CY2024Q1	us-gaap	Payments To Acquire Property Plant And Equipment PaymentsToAcquirePropertyPlantAndEquipment	169000000	usd
CY2023Q1	us-gaap	Payments To Acquire Property Plant And Equipment PaymentsToAcquirePropertyPlantAndEquipment	193000000	usd
CY2024Q1	us-gaap	Payments To Acquire Businesses Net Of Cash Acquired PaymentsToAcquireBusinessesNetOfCashAcquired	59000000	usd
CY2023Q1	us-gaap	Payments To Acquire Businesses Net Of Cash Acquired PaymentsToAcquireBusinessesNetOfCashAcquired	0	usd
CY2024Q1	us-gaap	Payments To Acquire Marketable Securities PaymentsToAcquireMarketableSecurities	379000000	usd
CY2023Q1	us-gaap	Payments To Acquire Marketable Securities PaymentsToAcquireMarketableSecurities	326000000	usd
CY2024Q1	us-gaap	Proceeds From Sale And Maturity Of Marketable Securities ProceedsFromSaleAndMaturityOfMarketableSecurities	431000000	usd
CY2023Q1	us-gaap	Proceeds From Sale And Maturity Of Marketable Securities ProceedsFromSaleAndMaturityOfMarketableSecurities	345000000	usd
CY2024Q1	us-gaap	Cash Divested From Deconsolidation CashDivestedFromDeconsolidation	174000000	usd
CY2023Q1	us-gaap	Cash Divested From Deconsolidation CashDivestedFromDeconsolidation	0	usd
CY2024Q1	us-gaap	Payments For Proceeds From Other Investing Activities PaymentsForProceedsFromOtherInvestingActivities	56000000	usd
CY2023Q1	us-gaap	Payments For Proceeds From Other Investing Activities PaymentsForProceedsFromOtherInvestingActivities	54000000	usd
CY2024Q1	us-gaap	Net Cash Provided By Used In Investing Activities NetCashProvidedByUsedInInvestingActivities	-406000000	usd
CY2023Q1	us-gaap	Net Cash Provided By Used In Investing Activities NetCashProvidedByUsedInInvestingActivities	-228000000	usd
CY2024Q1	us-gaap	Proceeds From Issuance Of Long Term Debt ProceedsFromIssuanceOfLongTermDebt	2398000000	usd
CY2023Q1	us-gaap	Proceeds From Issuance Of Long Term Debt ProceedsFromIssuanceOfLongTermDebt	43000000	usd
CY2024Q1	us-gaap	Proceeds From Repayments Of Commercial Paper ProceedsFromRepaymentsOfCommercialPaper	-887000000	usd
CY2023Q1	us-gaap	Proceeds From Repayments Of Commercial Paper ProceedsFromRepaymentsOfCommercialPaper	-29000000	usd
CY2024Q1	us-gaap	Repayments Of Long Term Debt And Capital Securities RepaymentsOfLongTermDebtAndCapitalSecurities	748000000	usd
CY2023Q1	us-gaap	Repayments Of Long Term Debt And Capital Securities RepaymentsOfLongTermDebtAndCapitalSecurities	142000000	usd
CY2024Q1	us-gaap	Payments Of Dividends PaymentsOfDividends	239000000	usd
CY2023Q1	us-gaap	Payments Of Dividends PaymentsOfDividends	222000000	usd
CY2024Q1	us-gaap	Proceeds From Payments For Other Financing Activities ProceedsFromPaymentsForOtherFinancingActivities	-25000000	usd
CY2023Q1	us-gaap	Proceeds From Payments For Other Financing Activities ProceedsFromPaymentsForOtherFinancingActivities	-13000000	usd
CY2024Q1	us-gaap	Net Cash Provided By Used In Financing Activities NetCashProvidedByUsedInFinancingActivities	499000000	usd
CY2023Q1	us-gaap	Net Cash Provided By Used In Financing Activities NetCashProvidedByUsedInFinancingActivities	-363000000	usd
CY2024Q1	us-gaap	Effect Of Exchange Rate On Cash Cash Equivalents Restricted Cash And Restricted Cash Equivalents EffectOfExchangeRateOnCashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents	-7000000	usd
CY2023Q1	us-gaap	Effect Of Exchange Rate On Cash Cash Equivalents Restricted Cash And Restricted Cash Equivalents EffectOfExchangeRateOnCashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents	-25000000	usd
CY2024Q1	us-gaap	Cash Cash Equivalents Restricted Cash And Restricted Cash Equivalents Period Increase Decrease Including Exchange Rate Effect CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsPeriodIncreaseDecreaseIncludingExchangeRateEffect	362000000	usd
CY2023Q1	us-gaap	Cash Cash Equivalents Restricted Cash And Restricted Cash Equivalents Period Increase Decrease Including Exchange Rate Effect CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsPeriodIncreaseDecreaseIncludingExchangeRateEffect	-121000000	usd
CY2023Q4	us-gaap	Cash Cash Equivalents Restricted Cash And Restricted Cash Equivalents CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents	2179000000	usd
CY2022Q4	us-gaap	Cash Cash Equivalents Restricted Cash And Restricted Cash Equivalents CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents	2101000000	usd
CY2024Q1	us-gaap	Cash Cash Equivalents Restricted Cash And Restricted Cash Equivalents CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents	2541000000	usd
CY2023Q1	us-gaap	Cash Cash Equivalents Restricted Cash And Restricted Cash Equivalents CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents	1980000000	usd
CY2023Q4	us-gaap	Stockholders Equity Including Portion Attributable To Noncontrolling Interest StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest	9904000000	usd
CY2024Q1	us-gaap	Other Comprehensive Income Other Net Of Tax OtherComprehensiveIncomeOtherNetOfTax	-122000000	usd
CY2024Q1	us-gaap	Common Stock Dividends Per Share Declared CommonStockDividendsPerShareDeclared	1.68
CY2024Q1	us-gaap	Dividends Common Stock Cash DividendsCommonStockCash	239000000	usd
CY2024Q1	us-gaap	Minority Interest Decrease From Distributions To Noncontrolling Interest Holders MinorityInterestDecreaseFromDistributionsToNoncontrollingInterestHolders	33000000	usd
CY2024Q1	us-gaap	Adjustments To Additional Paid In Capital Sharebased Compensation And Exercise Of Stock Options AdjustmentsToAdditionalPaidInCapitalSharebasedCompensationAndExerciseOfStockOptions	54000000	usd
CY2024Q1	cmi	Impact On Equity On Exchange Of Noncontrolling Interest In Subsidiary ImpactOnEquityOnExchangeOfNoncontrollingInterestInSubsidiary	-1490000000	usd
CY2024Q1	us-gaap	Stockholders Equity Other StockholdersEquityOther	-1000000	usd
CY2024Q1	us-gaap	Stockholders Equity Including Portion Attributable To Noncontrolling Interest StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest	10101000000	usd
CY2022Q4	us-gaap	Stockholders Equity Including Portion Attributable To Noncontrolling Interest StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest	9967000000	usd
CY2023Q1	us-gaap	Other Comprehensive Income Loss Net Of Tax OtherComprehensiveIncomeLossNetOfTax	70000000	usd
CY2023Q1	us-gaap	Common Stock Dividends Per Share Declared CommonStockDividendsPerShareDeclared	1.57
CY2023Q1	us-gaap	Dividends Common Stock Cash DividendsCommonStockCash	222000000	usd
CY2023Q1	us-gaap	Minority Interest Decrease From Distributions To Noncontrolling Interest Holders MinorityInterestDecreaseFromDistributionsToNoncontrollingInterestHolders	22000000	usd
CY2023Q1	us-gaap	Adjustments To Additional Paid In Capital Sharebased Compensation And Exercise Of Stock Options AdjustmentsToAdditionalPaidInCapitalSharebasedCompensationAndExerciseOfStockOptions	20000000	usd
CY2023Q1	us-gaap	Minority Interest Change In Redemption Value MinorityInterestChangeInRedemptionValue	-11000000	usd
CY2023Q1	us-gaap	Stockholders Equity Other StockholdersEquityOther	4000000	usd
CY2023Q1	us-gaap	Stockholders Equity Including Portion Attributable To Noncontrolling Interest StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest	10620000000	usd
CY2024Q1	us-gaap	Nature Of Operations NatureOfOperations	<div style="margin-bottom:8pt;margin-top:8pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">NOTE 1. NATURE OF OPERATIONS AND BASIS OF PRESENTATION</span></div><div style="margin-bottom:8pt;margin-top:8pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">Overview </span></div><div style="margin-bottom:8pt;margin-top:8pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Cummins Inc. (“Cummins,” “we,” “our” or “us”) was founded in 1919 as Cummins Engine Company, a corporation in Columbus, Indiana, and one of the first diesel engine manufacturers. In 2001, we changed our name to Cummins Inc. We are a global power solutions leader comprised of five business segments - Components, Engine, Distribution, Power Systems and Accelera - supported by our global manufacturing and extensive service and support network, skilled workforce and vast technical expertise. Our products range from advanced diesel, natural gas, electric and hybrid powertrains and powertrain-related components including aftertreatment, turbochargers, fuel systems, valvetrain technologies, controls systems, air handling systems, automated transmissions, axles, drivelines, brakes, suspension systems, electric power generation systems, batteries, electrified power systems, hydrogen production technologies and fuel cell products. We sell our products to original equipment manufacturers (OEMs), distributors, dealers and other customers worldwide. We serve our customers through a service network of approximately 450 wholly-owned, joint venture and independent distributor locations and more than 19,000 Cummins certified dealer locations in approximately 190 countries and territories.</span></div><div style="margin-bottom:8pt;margin-top:8pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">Divestiture of Atmus</span></div><div style="margin-bottom:8pt;margin-top:8pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">On March 18, 2024, we completed the divestiture of our remaining 80.5 percent ownership of Atmus Filtration Technologies Inc. (Atmus) common stock through a tax-free split-off. See NOTE 14, "ATMUS DIVESTITURE," for additional information.</span></div><div style="margin-bottom:8pt;margin-top:8pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">Settlement Agreements</span></div><div style="margin-bottom:8pt;margin-top:8pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">In December 2023, we announced that we reached an agreement in principle with the U.S. Environmental Protection Agency (EPA), the California Air Resources Board (CARB), the Environmental and Natural Resources Division of the U.S. Department of Justice and the California Attorney General's Office to resolve certain regulatory civil claims regarding our emissions certification and compliance process for certain engines primarily used in pick-up truck applications in the U.S., which became final and effective in April 2024 (collectively, the Settlement Agreements). See NOTE 11, “COMMITMENTS AND CONTINGENCIES,” for additional information.</span></div><div style="margin-bottom:8pt;margin-top:8pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">Interim Condensed Financial Statements</span></div><div style="margin-bottom:8pt;margin-top:8pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The unaudited </span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%">Condensed Consolidated Financial Statements</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"> reflect all adjustments which, in the opinion of management, are necessary for a fair statement of the results of operations, financial position and cash flows. All such adjustments are of a normal recurring nature. The </span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%">Condensed Consolidated Financial Statements</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"> were prepared in accordance with accounting principles in the United States of America (GAAP) pursuant to the rules and regulations of the Securities and Exchange Commission (SEC) for interim financial information. Certain information and footnote disclosures normally included in annual financial statements were condensed or omitted as permitted by such rules and regulations. </span></div><div style="margin-bottom:8pt;margin-top:8pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">These interim condensed consolidated financial statements should be read in conjunction with the </span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%">Consolidated Financial Statements</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"> included in our </span><span style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;text-decoration:underline"><a href="https://www.sec.gov/ix?doc=/Archives/edgar/data/26172/000002617224000012/cmi-20231231.htm" style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;text-decoration:underline">Annual Report on Form 10-K for the year ended December 31, 2023</a></span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">. Our interim period financial results for the three month periods presented are not necessarily indicative of results to be expected for any other interim period or for the entire year. The year-end </span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%">Condensed Consolidated Balance Sheet</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"> data was derived from audited financial statements but does not include all required annual disclosures.</span></div><div style="margin-bottom:8pt;margin-top:8pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">Reclassifications </span></div><div style="margin-bottom:8pt;margin-top:8pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Certain amounts for prior year periods were reclassified to conform to the current year presentation.</span></div><div style="margin-bottom:8pt;margin-top:8pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">Use of Estimates in Preparation of Financial Statements</span></div><div style="margin-bottom:8pt;margin-top:8pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Preparation of financial statements requires management to make estimates and assumptions that affect reported amounts presented and disclosed in our </span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%">Condensed Consolidated Financial Statements</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">. Significant estimates and assumptions in these </span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%">Condensed Consolidated Financial Statements </span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">require the exercise of judgment. Due to the inherent uncertainty involved in making estimates, actual results reported in future periods may be different from these estimates.</span></div><div style="margin-bottom:8pt;margin-top:8pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">Weighted-Average Diluted Shares Outstanding</span></div><div style="margin-bottom:8pt;margin-top:8pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The weighted-average diluted common shares outstanding exclude the anti-dilutive effect of certain stock options. The options excluded from diluted earnings per share were as follows:</span></div><div style="margin-bottom:8pt;margin-top:8pt;text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"> </span><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:40.138%"><tr><td style="width:1.0%"></td><td style="width:41.460%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:26.581%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:1.530%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:26.929%"></td><td style="width:0.1%"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="padding:0 1pt"></td><td colspan="9" style="padding:2px 1pt;text-align:center;vertical-align:middle"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">Three months ended</span></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:1pt;font-weight:700;line-height:100%"> </span></td><td colspan="9" style="padding:2px 1pt;text-align:center;vertical-align:middle"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">March 31,</span></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:1pt;font-weight:700;line-height:100%"> </span></td><td colspan="3" style="border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:middle"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">2024</span></td><td colspan="3" style="border-top:1pt solid #000;padding:0 1pt"></td><td colspan="3" style="border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:middle"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">2023</span></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Options excluded</span></td><td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">3,600</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"> </span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">4,833 </span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr></table></div><div style="margin-bottom:8pt;margin-top:8pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">Related Party Transactions</span></div><div style="margin-bottom:8pt;margin-top:8pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">In accordance with the provisions of various joint venture agreements, we may purchase products and components from our joint ventures, sell products and components to our joint ventures and our joint ventures may sell products and components to unrelated parties. </span></div><div style="margin-bottom:8pt;margin-top:8pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The following is a summary of sales to and purchases from nonconsolidated equity investees: </span></div><div style="margin-bottom:8pt;margin-top:8pt;text-align:center"><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:69.861%"><tr><td style="width:1.0%"></td><td style="width:65.102%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.794%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:14.804%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.794%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:14.806%"></td><td style="width:0.1%"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="9" style="padding:2px 1pt;text-align:center;vertical-align:middle"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">Three months ended </span></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:1pt;font-weight:700;line-height:100%"> </span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="9" style="padding:2px 1pt;text-align:center;vertical-align:middle"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">March 31,</span></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">In millions</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:middle"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">2024</span></td><td colspan="3" style="border-top:1pt solid #000;padding:0 1pt"></td><td colspan="3" style="border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:middle"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">2023</span></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Sales to nonconsolidated equity investees</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">351</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"> </span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:top"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">376 </span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:top"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Purchases from nonconsolidated equity investees</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">653</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"> </span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:top"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">704 </span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:top"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr style="height:8pt"><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr></table></div><div style="margin-bottom:8pt;margin-top:8pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:112%">The following is a summary of accounts receivable from and accounts payable to nonconsolidated equity investees:</span></div><div style="margin-bottom:8pt;margin-top:8pt;text-align:center"><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:99.166%"><tr><td style="width:1.0%"></td><td style="width:45.538%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.500%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:10.104%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.500%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:10.104%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.500%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:27.754%"></td><td style="width:0.1%"></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">In millions</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">March 31,<br/>2024</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">December 31,<br/>2023</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">Balance Sheet Location</span></td></tr><tr><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Accounts receivable from nonconsolidated equity investees</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">425</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"> </span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:top"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">530 </span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:top"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Accounts and notes receivable, net</span></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Accounts payable to nonconsolidated equity investees</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">325</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"> </span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:top"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">324 </span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:top"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Accounts payable (principally trade)</span></td></tr><tr style="height:6pt"><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td></tr></table></div><div style="margin-bottom:8pt;margin-top:8pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">Supply Chain Financing</span></div><div style="margin-bottom:8pt;margin-top:8pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">We currently have supply chain financing programs with financial intermediaries, which provide certain vendors the option to be paid by financial intermediaries earlier than the due date on the applicable invoice. When a vendor utilizes the program and receives an early payment from a financial intermediary, they take a discount on the invoice. We then pay the financial intermediary the face amount of the invoice on the original due date, which generally have 60 to 90 day payment terms. The maximum amount that we could have outstanding under the program was $512 million at March 31, 2024. We do not reimburse vendors for any costs they incur for participation in the program, their participation is completely voluntary and there are no assets pledged as security or other forms of guarantees provided for the committed payment to the finance provider or intermediary. As a result, all amounts owed to the financial intermediaries are presented as accounts payable in our </span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%">Condensed Consolidated Balance Sheets</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">. Amounts due to the financial intermediaries reflected in accounts payable at March 31, 2024, and December 31, 2023, were $193 million and $199 million, respectively.</span></div>
CY2024Q1	cmi	Company Owned And Independent Distributor Locations Number CompanyOwnedAndIndependentDistributorLocationsNumber	450	location
CY2024Q1	cmi	Countries And Territories Number CountriesAndTerritoriesNumber	190	country
CY2024Q1	us-gaap	Antidilutive Securities Excluded From Computation Of Earnings Per Share Amount AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount	3600	shares
CY2023Q1	us-gaap	Antidilutive Securities Excluded From Computation Of Earnings Per Share Amount AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount	4833	shares
CY2024Q1	cmi	Supply Chain Financing Program Maximum SupplyChainFinancingProgramMaximum	512000000	usd
CY2024Q1	us-gaap	Supplier Finance Program Obligation SupplierFinanceProgramObligation	193000000	usd
CY2023Q4	us-gaap	Supplier Finance Program Obligation SupplierFinanceProgramObligation	199000000	usd
CY2024Q1	us-gaap	Revenue Remaining Performance Obligation RevenueRemainingPerformanceObligation	3100000000	usd
CY2024Q1	us-gaap	Revenue Remaining Performance Obligation RevenueRemainingPerformanceObligation	1400000000	usd
CY2024Q1	us-gaap	Revenue Remaining Performance Obligation Expected Timing Of Satisfaction Period1 RevenueRemainingPerformanceObligationExpectedTimingOfSatisfactionPeriod1	P12M
CY2024Q1	us-gaap	Revenue Remaining Performance Obligation RevenueRemainingPerformanceObligation	1700000000	usd
CY2024Q1	us-gaap	Revenue Remaining Performance Obligation Expected Timing Of Satisfaction Period1 RevenueRemainingPerformanceObligationExpectedTimingOfSatisfactionPeriod1	P10Y
CY2024Q1	us-gaap	Contract With Customer Receivable Before Allowance For Credit Loss ContractWithCustomerReceivableBeforeAllowanceForCreditLoss	330000000	usd
CY2023Q4	us-gaap	Contract With Customer Receivable Before Allowance For Credit Loss ContractWithCustomerReceivableBeforeAllowanceForCreditLoss	303000000	usd
CY2024Q1	us-gaap	Contract With Customer Liability ContractWithCustomerLiability	2297000000	usd
CY2023Q4	us-gaap	Contract With Customer Liability ContractWithCustomerLiability	2186000000	usd
CY2024Q1	us-gaap	Contract With Customer Liability Revenue Recognized ContractWithCustomerLiabilityRevenueRecognized	248000000	usd
CY2023Q1	us-gaap	Contract With Customer Liability Revenue Recognized ContractWithCustomerLiabilityRevenueRecognized	206000000	usd
CY2024Q1	us-gaap	Revenues Revenues	8403000000	usd
CY2023Q1	us-gaap	Revenues Revenues	8453000000	usd
CY2024Q1	us-gaap	Defined Contribution Plan Cost Recognized DefinedContributionPlanCostRecognized	48000000	usd
CY2023Q1	us-gaap	Defined Contribution Plan Cost Recognized DefinedContributionPlanCostRecognized	43000000	usd
CY2024Q1	us-gaap	Income Loss From Equity Method Investments IncomeLossFromEquityMethodInvestments	123000000	usd
CY2023Q1	us-gaap	Income Loss From Equity Method Investments IncomeLossFromEquityMethodInvestments	119000000	usd
CY2024Q1	us-gaap	Effective Income Tax Rate Continuing Operations EffectiveIncomeTaxRateContinuingOperations	0.087
CY2023Q1	us-gaap	Effective Income Tax Rate Continuing Operations EffectiveIncomeTaxRateContinuingOperations	0.217
CY2024Q1	us-gaap	Other Tax Expense Benefit OtherTaxExpenseBenefit	-21000000	usd
CY2023Q1	us-gaap	Employee Service Share Based Compensation Tax Benefit From Compensation Expense EmployeeServiceShareBasedCompensationTaxBenefitFromCompensationExpense	3000000	usd
CY2024Q1	us-gaap	Available For Sale Debt Securities Amortized Cost Basis AvailableForSaleDebtSecuritiesAmortizedCostBasis	13000000	usd
CY2024Q1	us-gaap	Available For Sale Debt Securities Accumulated Gross Unrealized Gain Before Tax AvailableForSaleDebtSecuritiesAccumulatedGrossUnrealizedGainBeforeTax	0	usd
CY2024Q1	us-gaap	Available For Sale Securities Debt Securities AvailableForSaleSecuritiesDebtSecurities	13000000	usd
CY2023Q4	us-gaap	Available For Sale Debt Securities Amortized Cost Basis AvailableForSaleDebtSecuritiesAmortizedCostBasis	16000000	usd
CY2023Q4	us-gaap	Available For Sale Debt Securities Accumulated Gross Unrealized Gain Before Tax AvailableForSaleDebtSecuritiesAccumulatedGrossUnrealizedGainBeforeTax	0	usd
CY2023Q4	us-gaap	Available For Sale Securities Debt Securities AvailableForSaleSecuritiesDebtSecurities	16000000	usd
CY2024Q1	us-gaap	Debt Securities Trading And Equity Securities Fv Ni Cost DebtSecuritiesTradingAndEquitySecuritiesFvNiCost	504000000	usd
CY2024Q1	us-gaap	Marketable Securities Unrealized Gain Loss MarketableSecuritiesUnrealizedGainLoss	6000000	usd
CY2024Q1	us-gaap	Marketable Securities Current MarketableSecuritiesCurrent	510000000	usd
CY2023Q4	us-gaap	Debt Securities Trading And Equity Securities Fv Ni Cost DebtSecuritiesTradingAndEquitySecuritiesFvNiCost	556000000	usd
CY2023	us-gaap	Marketable Securities Unrealized Gain Loss MarketableSecuritiesUnrealizedGainLoss	6000000	usd
CY2023Q4	us-gaap	Marketable Securities Current MarketableSecuritiesCurrent	562000000	usd
CY2024Q1	us-gaap	Proceeds From Sale Of Held To Maturity Securities ProceedsFromSaleOfHeldToMaturitySecurities	426000000	usd
CY2023Q1	us-gaap	Proceeds From Sale Of Held To Maturity Securities ProceedsFromSaleOfHeldToMaturitySecurities	276000000	usd
CY2024Q1	us-gaap	Proceeds From Maturities Prepayments And Calls Of Held To Maturity Securities ProceedsFromMaturitiesPrepaymentsAndCallsOfHeldToMaturitySecurities	5000000	usd
CY2023Q1	us-gaap	Proceeds From Maturities Prepayments And Calls Of Held To Maturity Securities ProceedsFromMaturitiesPrepaymentsAndCallsOfHeldToMaturitySecurities	69000000	usd
CY2024Q1	us-gaap	Proceeds From Sale And Maturity Of Marketable Securities ProceedsFromSaleAndMaturityOfMarketableSecurities	431000000	usd
CY2023Q1	us-gaap	Proceeds From Sale And Maturity Of Marketable Securities ProceedsFromSaleAndMaturityOfMarketableSecurities	345000000	usd
CY2024Q1	us-gaap	Inventory Finished Goods InventoryFinishedGoods	2931000000	usd
CY2023Q4	us-gaap	Inventory Finished Goods InventoryFinishedGoods	2770000000	usd
CY2024Q1	us-gaap	Inventory Work In Process And Raw Materials InventoryWorkInProcessAndRawMaterials	3049000000	usd
CY2023Q4	us-gaap	Inventory Work In Process And Raw Materials InventoryWorkInProcessAndRawMaterials	3156000000	usd
CY2024Q1	us-gaap	Fifo Inventory Amount FIFOInventoryAmount	5980000000	usd
CY2023Q4	us-gaap	Fifo Inventory Amount FIFOInventoryAmount	5926000000	usd
CY2024Q1	us-gaap	Inventory Lifo Reserve InventoryLIFOReserve	222000000	usd
CY2023Q4	us-gaap	Inventory Lifo Reserve InventoryLIFOReserve	249000000	usd
CY2024Q1	us-gaap	Inventory Net InventoryNet	5758000000	usd
CY2023Q4	us-gaap	Inventory Net InventoryNet	5677000000	usd
CY2024Q1	us-gaap	Deferred Tax Assets Tax Credit Carryforwards General Business DeferredTaxAssetsTaxCreditCarryforwardsGeneralBusiness	950000000	usd
CY2023Q4	us-gaap	Deferred Tax Assets Tax Credit Carryforwards General Business DeferredTaxAssetsTaxCreditCarryforwardsGeneralBusiness	1082000000	usd
CY2024Q1	us-gaap	Operating Lease Right Of Use Asset OperatingLeaseRightOfUseAsset	455000000	usd
CY2023Q4	us-gaap	Operating Lease Right Of Use Asset OperatingLeaseRightOfUseAsset	501000000	usd
CY2024Q1	us-gaap	Cash Surrender Value Of Life Insurance CashSurrenderValueOfLifeInsurance	419000000	usd
CY2023Q4	us-gaap	Cash Surrender Value Of Life Insurance CashSurrenderValueOfLifeInsurance	417000000	usd
CY2024Q1	us-gaap	Other Assets Miscellaneous Noncurrent OtherAssetsMiscellaneousNoncurrent	550000000	usd
CY2023Q4	us-gaap	Other Assets Miscellaneous Noncurrent OtherAssetsMiscellaneousNoncurrent	543000000	usd
CY2024Q1	us-gaap	Other Assets Noncurrent OtherAssetsNoncurrent	2374000000	usd
CY2023Q4	us-gaap	Other Assets Noncurrent OtherAssetsNoncurrent	2543000000	usd
CY2024Q1	us-gaap	Loss Contingency Accrual Carrying Value Current LossContingencyAccrualCarryingValueCurrent	1938000000	usd
CY2023Q4	us-gaap	Loss Contingency Accrual Carrying Value Current LossContingencyAccrualCarryingValueCurrent	1938000000	usd
CY2024Q1	us-gaap	Accrued Income Taxes AccruedIncomeTaxes	361000000	usd
CY2023Q4	us-gaap	Accrued Income Taxes AccruedIncomeTaxes	242000000	usd
CY2024Q1	us-gaap	Accrued Marketing Costs Current AccruedMarketingCostsCurrent	340000000	usd
CY2023Q4	us-gaap	Accrued Marketing Costs Current AccruedMarketingCostsCurrent	399000000	usd
CY2024Q1	us-gaap	Accrual For Taxes Other Than Income Taxes Current And Noncurrent AccrualForTaxesOtherThanIncomeTaxesCurrentAndNoncurrent	222000000	usd
CY2023Q4	us-gaap	Accrual For Taxes Other Than Income Taxes Current And Noncurrent AccrualForTaxesOtherThanIncomeTaxesCurrentAndNoncurrent	296000000	usd
CY2024Q1	us-gaap	Operating Lease Liability Current OperatingLeaseLiabilityCurrent	129000000	usd
CY2023Q4	us-gaap	Operating Lease Liability Current OperatingLeaseLiabilityCurrent	138000000	usd
CY2024Q1	us-gaap	Other Accrued Liabilities Current OtherAccruedLiabilitiesCurrent	707000000	usd
CY2023Q4	us-gaap	Other Accrued Liabilities Current OtherAccruedLiabilitiesCurrent	741000000	usd
CY2024Q1	us-gaap	Accrued Liabilities Current AccruedLiabilitiesCurrent	3697000000	usd
CY2023Q4	us-gaap	Accrued Liabilities Current AccruedLiabilitiesCurrent	3754000000	usd
CY2024Q1	us-gaap	Product Warranty Accrual Noncurrent ProductWarrantyAccrualNoncurrent	816000000	usd
CY2023Q4	us-gaap	Product Warranty Accrual Noncurrent ProductWarrantyAccrualNoncurrent	777000000	usd
CY2024Q1	us-gaap	Defined Benefit Pension Plan Liabilities Noncurrent DefinedBenefitPensionPlanLiabilitiesNoncurrent	495000000	usd
CY2023Q4	us-gaap	Defined Benefit Pension Plan Liabilities Noncurrent DefinedBenefitPensionPlanLiabilitiesNoncurrent	530000000	usd
CY2024Q1	us-gaap	Deferred Income Taxes And Other Tax Liabilities Noncurrent DeferredIncomeTaxesAndOtherTaxLiabilitiesNoncurrent	355000000	usd
CY2023Q4	us-gaap	Deferred Income Taxes And Other Tax Liabilities Noncurrent DeferredIncomeTaxesAndOtherTaxLiabilitiesNoncurrent	530000000	usd
CY2024Q1	us-gaap	Operating Lease Liability Noncurrent OperatingLeaseLiabilityNoncurrent	332000000	usd
CY2023Q4	us-gaap	Operating Lease Liability Noncurrent OperatingLeaseLiabilityNoncurrent	374000000	usd
CY2024Q1	us-gaap	Deferred Compensation Liability Classified Noncurrent DeferredCompensationLiabilityClassifiedNoncurrent	186000000	usd
CY2023Q4	us-gaap	Deferred Compensation Liability Classified Noncurrent DeferredCompensationLiabilityClassifiedNoncurrent	213000000	usd
CY2024Q1	us-gaap	Derivative Instruments And Hedges Liabilities Noncurrent DerivativeInstrumentsAndHedgesLiabilitiesNoncurrent	124000000	usd
CY2023Q4	us-gaap	Derivative Instruments And Hedges Liabilities Noncurrent DerivativeInstrumentsAndHedgesLiabilitiesNoncurrent	117000000	usd
CY2024Q1	us-gaap	Other Postretirement Defined Benefit Plan Liabilities Current And Noncurrent OtherPostretirementDefinedBenefitPlanLiabilitiesCurrentAndNoncurrent	123000000	usd
CY2023Q4	us-gaap	Other Postretirement Defined Benefit Plan Liabilities Current And Noncurrent OtherPostretirementDefinedBenefitPlanLiabilitiesCurrentAndNoncurrent	131000000	usd
CY2024Q1	us-gaap	Tax Cuts And Jobs Act Of2017 Transition Tax For Accumulated Foreign Earnings Liability TaxCutsAndJobsActOf2017TransitionTaxForAccumulatedForeignEarningsLiability	111000000	usd
CY2023Q4	us-gaap	Tax Cuts And Jobs Act Of2017 Transition Tax For Accumulated Foreign Earnings Liability TaxCutsAndJobsActOf2017TransitionTaxForAccumulatedForeignEarningsLiability	111000000	usd
CY2024Q1	us-gaap	Other Accrued Liabilities Noncurrent OtherAccruedLiabilitiesNoncurrent	666000000	usd
CY2023Q4	us-gaap	Other Accrued Liabilities Noncurrent OtherAccruedLiabilitiesNoncurrent	647000000	usd
CY2024Q1	us-gaap	Other Liabilities Noncurrent OtherLiabilitiesNoncurrent	3208000000	usd
CY2023Q4	us-gaap	Other Liabilities Noncurrent OtherLiabilitiesNoncurrent	3430000000	usd
CY2024Q1	us-gaap	Short Term Bank Loans And Notes Payable ShortTermBankLoansAndNotesPayable	342000000	usd
CY2023Q4	us-gaap	Short Term Bank Loans And Notes Payable ShortTermBankLoansAndNotesPayable	280000000	usd
CY2024Q1	us-gaap	Commercial Paper CommercialPaper	609000000	usd
CY2023Q4	us-gaap	Commercial Paper CommercialPaper	1496000000	usd
CY2024Q1	us-gaap	Line Of Credit Facility Maximum Borrowing Capacity LineOfCreditFacilityMaximumBorrowingCapacity	4000000000	usd
CY2024Q1	us-gaap	Commercial Paper CommercialPaper	609000000	usd
CY2024Q1	us-gaap	Line Of Credit Facility Maximum Borrowing Capacity LineOfCreditFacilityMaximumBorrowingCapacity	4000000000	usd
CY2024Q1	us-gaap	Line Of Credit Facility Remaining Borrowing Capacity LineOfCreditFacilityRemainingBorrowingCapacity	3400000000	usd
CY2024Q1	us-gaap	Other Long Term Debt OtherLongTermDebt	90000000	usd
CY2023Q4	us-gaap	Other Long Term Debt OtherLongTermDebt	94000000	usd
CY2024Q1	us-gaap	Debt Instrument Unamortized Discount DebtInstrumentUnamortizedDiscount	100000000	usd
CY2023Q4	us-gaap	Debt Instrument Unamortized Discount DebtInstrumentUnamortizedDiscount	72000000	usd
CY2024Q1	us-gaap	Liabilities Fair Value Adjustment LiabilitiesFairValueAdjustment	-111000000	usd
CY2023	us-gaap	Liabilities Fair Value Adjustment LiabilitiesFairValueAdjustment	-96000000	usd
CY2024Q1	us-gaap	Finance Lease Liability FinanceLeaseLiability	122000000	usd
CY2023Q4	us-gaap	Finance Lease Liability FinanceLeaseLiability	111000000	usd
CY2024Q1	us-gaap	Debt And Capital Lease Obligations DebtAndCapitalLeaseObligations	5884000000	usd
CY2023Q4	us-gaap	Debt And Capital Lease Obligations DebtAndCapitalLeaseObligations	4920000000	usd
CY2024Q1	us-gaap	Long Term Debt Current LongTermDebtCurrent	113000000	usd
CY2023Q4	us-gaap	Long Term Debt Current LongTermDebtCurrent	118000000	usd
CY2024Q1	us-gaap	Long Term Debt And Capital Lease Obligations LongTermDebtAndCapitalLeaseObligations	5771000000	usd
CY2023Q4	us-gaap	Long Term Debt And Capital Lease Obligations LongTermDebtAndCapitalLeaseObligations	4802000000	usd
CY2024Q1	us-gaap	Unsecured Debt UnsecuredDebt	2250000000	usd
CY2024Q1	us-gaap	Proceeds From Issuance Of Debt ProceedsFromIssuanceOfDebt	2200000000	usd
CY2024Q1	us-gaap	Long Term Debt Maturities Repayments Of Principal Remainder Of Fiscal Year LongTermDebtMaturitiesRepaymentsOfPrincipalRemainderOfFiscalYear	101000000	usd
CY2024Q1	us-gaap	Long Term Debt Maturities Repayments Of Principal In Next Twelve Months LongTermDebtMaturitiesRepaymentsOfPrincipalInNextTwelveMonths	1128000000	usd
CY2024Q1	us-gaap	Long Term Debt Maturities Repayments Of Principal In Year Two LongTermDebtMaturitiesRepaymentsOfPrincipalInYearTwo	41000000	usd
CY2024Q1	us-gaap	Long Term Debt Maturities Repayments Of Principal In Year Three LongTermDebtMaturitiesRepaymentsOfPrincipalInYearThree	76000000	usd
CY2024Q1	us-gaap	Long Term Debt Maturities Repayments Of Principal In Year Four LongTermDebtMaturitiesRepaymentsOfPrincipalInYearFour	267000000	usd
CY2024Q1	us-gaap	Long Term Debt Fair Value LongTermDebtFairValue	6491000000	usd
CY2023Q4	us-gaap	Long Term Debt Fair Value LongTermDebtFairValue	6375000000	usd
CY2024Q1	us-gaap	Debt Instrument Carrying Amount DebtInstrumentCarryingAmount	6835000000	usd
CY2023Q4	us-gaap	Debt Instrument Carrying Amount DebtInstrumentCarryingAmount	6696000000	usd
CY2023Q4	us-gaap	Product Warranty Accrual ProductWarrantyAccrual	2497000000	usd
CY2022Q4	us-gaap	Product Warranty Accrual ProductWarrantyAccrual	2477000000	usd
CY2024Q1	us-gaap	Standard Product Warranty Accrual Warranties Issued StandardProductWarrantyAccrualWarrantiesIssued	160000000	usd
CY2023Q1	us-gaap	Standard Product Warranty Accrual Warranties Issued StandardProductWarrantyAccrualWarrantiesIssued	146000000	usd
CY2024Q1	us-gaap	Extended Product Warranty Accrual Warranties Issued ExtendedProductWarrantyAccrualWarrantiesIssued	96000000	usd
CY2023Q1	us-gaap	Extended Product Warranty Accrual Warranties Issued ExtendedProductWarrantyAccrualWarrantiesIssued	102000000	usd
CY2024Q1	us-gaap	Product Warranty Accrual Warranties Issued ProductWarrantyAccrualWarrantiesIssued	6000000	usd
CY2023Q1	us-gaap	Product Warranty Accrual Warranties Issued ProductWarrantyAccrualWarrantiesIssued	6000000	usd
CY2024Q1	us-gaap	Product Warranty Accrual Payments ProductWarrantyAccrualPayments	176000000	usd
CY2023Q1	us-gaap	Product Warranty Accrual Payments ProductWarrantyAccrualPayments	143000000	usd
CY2024Q1	us-gaap	Extended Product Warranty Accrual Period Increase Decrease ExtendedProductWarrantyAccrualPeriodIncreaseDecrease	-77000000	usd
CY2023Q1	us-gaap	Extended Product Warranty Accrual Period Increase Decrease ExtendedProductWarrantyAccrualPeriodIncreaseDecrease	-75000000	usd
CY2024Q1	us-gaap	Extended Product Warranty Accrual Preexisting Increase Decrease ExtendedProductWarrantyAccrualPreexistingIncreaseDecrease	51000000	usd
CY2023Q1	us-gaap	Extended Product Warranty Accrual Preexisting Increase Decrease ExtendedProductWarrantyAccrualPreexistingIncreaseDecrease	10000000	usd
CY2024Q1	us-gaap	Standard And Extended Product Warranty Accrual Foreign Currency Translation Gain Loss StandardAndExtendedProductWarrantyAccrualForeignCurrencyTranslationGainLoss	-18000000	usd
CY2023Q1	us-gaap	Standard And Extended Product Warranty Accrual Foreign Currency Translation Gain Loss StandardAndExtendedProductWarrantyAccrualForeignCurrencyTranslationGainLoss	7000000	usd
CY2024Q1	us-gaap	Product Warranty Accrual ProductWarrantyAccrual	2539000000	usd
CY2023Q1	us-gaap	Product Warranty Accrual ProductWarrantyAccrual	2530000000	usd
CY2024Q1	us-gaap	Product Liability Contingency Third Party Recovery ProductLiabilityContingencyThirdPartyRecovery	22000000	usd
CY2023Q1	us-gaap	Product Liability Contingency Third Party Recovery ProductLiabilityContingencyThirdPartyRecovery	10000000	usd
CY2024Q1	us-gaap	Deferred Revenue DeferredRevenue	1071000000	usd
CY2023Q4	us-gaap	Deferred Revenue DeferredRevenue	1053000000	usd
CY2024Q1	us-gaap	Standard Product Warranty Accrual StandardProductWarrantyAccrual	1468000000	usd
CY2023Q4	us-gaap	Standard Product Warranty Accrual StandardProductWarrantyAccrual	1444000000	usd
CY2024Q1	us-gaap	Product Warranty Accrual ProductWarrantyAccrual	2539000000	usd
CY2023Q4	us-gaap	Product Warranty Accrual ProductWarrantyAccrual	2497000000	usd
CY2023Q4	us-gaap	Loss Contingency Loss In Period LossContingencyLossInPeriod	2000000000	usd
CY2022	us-gaap	Product Liability Accrual Period Expense ProductLiabilityAccrualPeriodExpense	59000000	usd
CY2024Q1	us-gaap	Guarantee Obligations Maximum Exposure GuaranteeObligationsMaximumExposure	39000000	usd
CY2024Q1	us-gaap	Unrecorded Unconditional Purchase Obligation Balance Sheet Amount UnrecordedUnconditionalPurchaseObligationBalanceSheetAmount	584000000	usd
CY2024Q1	us-gaap	Purchase Obligation PurchaseObligation	64000000	usd
CY2024Q1	us-gaap	Guarantee Obligations Current Carrying Value GuaranteeObligationsCurrentCarryingValue	192000000	usd
CY2024Q1	us-gaap	Other Comprehensive Income Loss Before Reclassifications Before Tax OtherComprehensiveIncomeLossBeforeReclassificationsBeforeTax	-118000000	usd
CY2024Q1	us-gaap	Other Comprehensive Income Loss Tax Portion Attributable To Parent1 OtherComprehensiveIncomeLossTaxPortionAttributableToParent1	4000000	usd
CY2024Q1	us-gaap	Other Comprehensive Income Loss Before Reclassifications Net Of Tax OtherComprehensiveIncomeLossBeforeReclassificationsNetOfTax	-122000000	usd
CY2024Q1	us-gaap	Reclassification From Accumulated Other Comprehensive Income Current Period Net Of Tax ReclassificationFromAccumulatedOtherComprehensiveIncomeCurrentPeriodNetOfTax	-61000000	usd
CY2024Q1	us-gaap	Other Comprehensive Income Loss Net Of Tax OtherComprehensiveIncomeLossNetOfTax	-61000000	usd
CY2023Q1	us-gaap	Other Comprehensive Income Loss Before Reclassifications Before Tax OtherComprehensiveIncomeLossBeforeReclassificationsBeforeTax	62000000	usd
CY2023Q1	us-gaap	Other Comprehensive Income Loss Tax Portion Attributable To Parent1 OtherComprehensiveIncomeLossTaxPortionAttributableToParent1	-7000000	usd
CY2023Q1	us-gaap	Other Comprehensive Income Loss Before Reclassifications Net Of Tax OtherComprehensiveIncomeLossBeforeReclassificationsNetOfTax	69000000	usd
CY2023Q1	us-gaap	Reclassification From Accumulated Other Comprehensive Income Current Period Net Of Tax ReclassificationFromAccumulatedOtherComprehensiveIncomeCurrentPeriodNetOfTax	-1000000	usd
CY2023Q1	us-gaap	Other Comprehensive Income Loss Net Of Tax OtherComprehensiveIncomeLossNetOfTax	70000000	usd
CY2024Q1	us-gaap	Increase Decrease In Fair Value Of Interest Rate Fair Value Hedging Instruments1 IncreaseDecreaseInFairValueOfInterestRateFairValueHedgingInstruments1	-10000000	usd
CY2024Q1	us-gaap	Increase Decrease In Fair Value Of Hedged Item In Interest Rate Fair Value Hedge1 IncreaseDecreaseInFairValueOfHedgedItemInInterestRateFairValueHedge1	14000000	usd
CY2023Q1	us-gaap	Increase Decrease In Fair Value Of Interest Rate Fair Value Hedging Instruments1 IncreaseDecreaseInFairValueOfInterestRateFairValueHedgingInstruments1	27000000	usd
CY2023Q1	us-gaap	Increase Decrease In Fair Value Of Hedged Item In Interest Rate Fair Value Hedge1 IncreaseDecreaseInFairValueOfHedgedItemInInterestRateFairValueHedge1	-22000000	usd
CY2024Q1	us-gaap	Derivative Assets Liabilities At Fair Value Net DerivativeAssetsLiabilitiesAtFairValueNet	13000000	usd
CY2023Q4	us-gaap	Derivative Assets Liabilities At Fair Value Net DerivativeAssetsLiabilitiesAtFairValueNet	4000000	usd
CY2024Q1	us-gaap	Derivative Net Liability Position Aggregate Fair Value DerivativeNetLiabilityPositionAggregateFairValue	130000000	usd
CY2023Q4	us-gaap	Derivative Net Liability Position Aggregate Fair Value DerivativeNetLiabilityPositionAggregateFairValue	148000000	usd
CY2024Q1	cmi	Discount On Exchange Ratio DiscountOnExchangeRatio	0.07	rate
CY2024Q1	cmi	Transitional Services Agreement Term TransitionalServicesAgreementTerm	P24Y
CY2024Q1	us-gaap	Amortization Of Debt Discount Premium AmortizationOfDebtDiscountPremium	3000000	usd
CY2023Q1	us-gaap	Amortization Of Debt Discount Premium AmortizationOfDebtDiscountPremium	1000000	usd
CY2024Q1	us-gaap	Interest Expense InterestExpense	89000000	usd
CY2023Q1	us-gaap	Interest Expense InterestExpense	87000000	usd
CY2024Q1	us-gaap	Other Depreciation And Amortization OtherDepreciationAndAmortization	262000000	usd
CY2023Q1	us-gaap	Other Depreciation And Amortization OtherDepreciationAndAmortization	245000000	usd
CY2024Q1	us-gaap	Income Loss From Continuing Operations Before Income Taxes Extraordinary Items Noncontrolling Interest IncomeLossFromContinuingOperationsBeforeIncomeTaxesExtraordinaryItemsNoncontrollingInterest	2221000000	usd
CY2023Q1	us-gaap	Income Loss From Continuing Operations Before Income Taxes Extraordinary Items Noncontrolling Interest IncomeLossFromContinuingOperationsBeforeIncomeTaxesExtraordinaryItemsNoncontrollingInterest	1029000000	usd
CY2024Q1	ecd	Non Rule10b51 Arr Adopted Flag NonRule10b51ArrAdoptedFlag	false
CY2024Q1	ecd	Rule10b51 Arr Trmntd Flag Rule10b51ArrTrmntdFlag	false
CY2024Q1	ecd	Rule10b51 Arr Adopted Flag Rule10b51ArrAdoptedFlag	false
CY2024Q1	ecd	Non Rule10b51 Arr Trmntd Flag NonRule10b51ArrTrmntdFlag	false

Files In Submission

Name	View Source	Status
0000026172-24-000023-index-headers.html	Edgar Link	pending
0000026172-24-000023-index.html	Edgar Link	pending
0000026172-24-000023.txt	Edgar Link	pending
0000026172-24-000023-xbrl.zip	Edgar Link	pending
cmi-20240331.htm	Edgar Link	pending
cmi-20240331.xsd	Edgar Link	pending
cmi-20240331_g1.jpg	Edgar Link	pending
cmi2024q110-qex10.htm	Edgar Link	pending
cmi2024q110-qex31a.htm	Edgar Link	pending
cmi2024q110-qex31b.htm	Edgar Link	pending
cmi2024q110-qex32.htm	Edgar Link	pending
cmi-20240331_cal.xml	Edgar Link	unprocessable
cmi-20240331_def.xml	Edgar Link	unprocessable
cmi-20240331_lab.xml	Edgar Link	unprocessable
cmi-20240331_pre.xml	Edgar Link	unprocessable
FilingSummary.xml	Edgar Link	unprocessable
cmi-20240331_htm.xml	Edgar Link	completed
Financial_Report.xlsx	Edgar Link	pending
MetaLinks.json	Edgar Link	pending
R1.htm	Edgar Link	pending
R10.htm	Edgar Link	pending
R11.htm	Edgar Link	pending
R12.htm	Edgar Link	pending
R13.htm	Edgar Link	pending
R14.htm	Edgar Link	pending
R15.htm	Edgar Link	pending
R16.htm	Edgar Link	pending
R17.htm	Edgar Link	pending
R18.htm	Edgar Link	pending
R19.htm	Edgar Link	pending
R2.htm	Edgar Link	pending
R20.htm	Edgar Link	pending
R21.htm	Edgar Link	pending
R22.htm	Edgar Link	pending
R23.htm	Edgar Link	pending
R24.htm	Edgar Link	pending
R25.htm	Edgar Link	pending
R26.htm	Edgar Link	pending
R27.htm	Edgar Link	pending
R28.htm	Edgar Link	pending
R29.htm	Edgar Link	pending
R3.htm	Edgar Link	pending
R30.htm	Edgar Link	pending
R31.htm	Edgar Link	pending
R32.htm	Edgar Link	pending
R33.htm	Edgar Link	pending
R34.htm	Edgar Link	pending
R35.htm	Edgar Link	pending
R36.htm	Edgar Link	pending
R37.htm	Edgar Link	pending
R38.htm	Edgar Link	pending
R39.htm	Edgar Link	pending
R4.htm	Edgar Link	pending
R40.htm	Edgar Link	pending
R41.htm	Edgar Link	pending
R42.htm	Edgar Link	pending
R43.htm	Edgar Link	pending
R44.htm	Edgar Link	pending
R45.htm	Edgar Link	pending
R46.htm	Edgar Link	pending
R47.htm	Edgar Link	pending
R48.htm	Edgar Link	pending
R49.htm	Edgar Link	pending
R5.htm	Edgar Link	pending
R50.htm	Edgar Link	pending
R51.htm	Edgar Link	pending
R52.htm	Edgar Link	pending
R53.htm	Edgar Link	pending
R54.htm	Edgar Link	pending
R55.htm	Edgar Link	pending
R56.htm	Edgar Link	pending
R6.htm	Edgar Link	pending
R7.htm	Edgar Link	pending
R8.htm	Edgar Link	pending
R9.htm	Edgar Link	pending
report.css	Edgar Link	pending
Show.js	Edgar Link	pending

Create your account

Find Stocks Worth Researching

Deeply Understand Businesses

Value Businesses Intelligently

$CMI
CUMMINS INC Stock $cmi

2024 Q1 Form 10-Q Financial Statement

#000002617224000023 Filed on May 02, 2024

Income Statement

Balance Sheet

Cashflow Statement

Facts In Submission

Files In Submission

$CMI CUMMINS INC Stock $cmi

2024 Q1 Form 10-Q Financial Statement

#000002617224000023 Filed on May 02, 2024

Income Statement

Balance Sheet

Cashflow Statement

Facts In Submission

Files In Submission

$CMI
CUMMINS INC Stock $cmi